Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARα with clofibrate

Toxicology and Applied Pharmacology

Volumn 230, Issue 3, 2008, Pages 327-337

  Donthamsetty, Shashikiran ^a   Bhave, Vishakha S ^a   Mitra, Mayurranjan S ^a   Latendresse, John R ^b   Mehendale, Harihara M ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b Pathology Associates International   (United States)

Author keywords

Acetaminophen; Hepatotoxicity; Methionine and choline deficient diet; Nonalcoholic steatohepatitis; Tissue repair

Indexed keywords

CARBON 14; CHOLINE; CLOFIBRATE; CYTOCHROME P450 2E1; METHIONINE; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIVISION; CONTROLLED STUDY; COVALENT BOND; DEATH; DISEASE MODEL; DNA SYNTHESIS; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; LETHALITY; LIVER INJURY; LIVER TOXICITY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; SWISS WEBSTER MOUSE;

ACETAMINOPHEN; ADENOSINE TRIPHOSPHATE; ALANINE TRANSAMINASE; ANIMALS; CLOFIBRATE; CYTOCHROME P-450 CYP2E1; CYTOPROTECTION; DNA REPLICATION; FATTY LIVER; LIVER; MALE; MICE; OXIDATIVE STRESS; PPAR ALPHA; PROLIFERATING CELL NUCLEAR ANTIGEN;

MUS;

EID: 46749134245     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.02.031     Document Type: Article

References (55)

1. Anderson S.P., Yoon L., Richard E.B., Dunn C.S., Cattley R.C., and Corton J.C. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology 36 (2002) 544-554
2. Anstee Q.M., and Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87 (2006) 1-16
3. Bacon B.R., Farahvash M.J., Janney C.G., and Neuschwander-Tetri B.A. Nonalcoholicsteatohepatitis: an expanded clinical entity. Gastroenterology 107 (1994) 1103-1109
4. Bhave V.S., Donthamsetty S., Latendresse J.R., and Mehendale H.M. Inhibition of COX-2 aggravates secretory phospholipase A2-mediated progression of acute liver injury. Toxicol. Appl. Pharmacol. 228 (2008) 239-246
5. Bhave V.S., Donthamsetty S., Latendresse J.R., Muskhelishvili L., and Mehendale H.M. Secretory phospholipase A2 mediates progression of acute liver injury in the absence of sufficient COX-2. Toxicol. Appl. Pharmacol. 228 (2008) 225-238
6. Chen C., Hennig G.E., Whiteley H.E., Corton J.C., and Manautou J.E. Peroxisome proliferator-activated receptor alpha-null mice lack resistance to acetaminophen hepatotoxicity following clofibrate exposure. Toxicol. Sci. 57 (2000) 338-344
7. Chen C., Hennig G.E., Whiteley H.E., and Manautou J.E. Protection against acetaminophen hepatotoxicity by clofibrate pretreatment: role of catalase induction. J. Biochem. Mol. Toxicol. 16 (2002) 227-234
8. Corton J.C., Anderson S.P., and Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 491-518
9. Corton J.C., Apte U., Anderson S.P., Limaye P., Yoon L., Latendresse J., Dunn C., Everitt J.I., Voss K.A., Swanson C., Kimbrough C., Wong J.S., Gill S.S., Chandraratna R.A., Kwak M.K., Kensler T.W., Stulnig T.M., Steffensen K.R., Gustafsson J.A., and Mehendale H.M. Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors. J. Biol. Chem. 279 (2004) 46204-46212
10. Donthamsetty S., Bhave V.S., Mitra M.S., Latendresse J.R., and Mehendale H.M. Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity. Hepatology 45 (2007) 391-403
11. Hazelton G.A., Hjelle J.J., and Klaassen C.D. Effects of butylated hydroxyanisole on hepatic glucuronidation capacity in mice. Toxicol. Appl. Pharmacol. 78 (1985) 280-290
12. Hertz R., and Bar-Tana J. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans. Toxicol. Lett. 102-103 (1998) 85-90
13. Jeffrey P.D., Tong L., and Pavletich N.P. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors. Genes Dev. 14 (2000) 3115-3125
14. Jollow D.J., Mitchell J.R., Potter W.Z., Davis D.C., Gillette J.R., and Brodie B.B. Acetaminophen-induced hepatic necrosis II. Role of covalent binding in vivo. J. Pharmacol. Exp. Ther. 187 (1973) 195-202
15. Kirsch R., Clarkson V., Shephard E.G., Marais D.A., Jaffer M.A., Woodburne V.E., Kirsch R.E., and Hall Pde L. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18 (2003) 1272-1282
16. Kodavanti P.R., Kodavanti U.P., and Mehendale H.M. Altered hepatic energy status in chlordecone (Kepone)-potentiated CCl4 hepatotoxicity. Biochem. Pharmacol. 40 (1990) 859-866
17. Koteish A., Yang S., Lin H., Huang J., and Diehl A.M. Ethanol induces redox-sensitive cell-cycle inhibitors and inhibits liver regeneration after partial hepatectomy. Alcohol. Clin. Exp. Res. 26 (2002) 1710-1718
18. Kulkarni S.G., Warbritton A., Bucci T.J., and Mehendale H.M. Antimitotic intervention with colchicine alters the outcome of o-DCB-induced hepatotoxicity in Fischer 344 rats. Toxicology 120 (1997) 79-88
19. Latchoumycandane C., Seah Q.M., Tan R.C., Sattabongkot J., Beerheide W., and Boelsterli U.A. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes. Toxicol. Appl. Pharmacol. 217 (2006) 125-133
20. Latchoumycandane C., Goh C.W., Ong M.M., and Boelsterli U.A. Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology 45 (2007) 412-421
21. Lee R.G. Nonalcoholic steatohepatitis: a study of 49 patients. Hum. Pathol. 20 (1989) 594-598
22. Limaye P.B., Apte U.M., Shankar K., Bucci T.J., Warbritton A., and Mehendale H.M. Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicol. Appl. Pharmacol. 191 (2003) 211-226
23. Limaye P.B., Bhave V.S., Palkar P.S., Apte U.M., Sawant S.P., Yu S., Latendresse J.R., Reddy J.K., and Mehendale H.M. Upregulation of calpastatin in regenerating and developing rat liver: role in resistance against hepatotoxicity. Hepatology 44 (2006) 379-388
24. Manautou J.E., Hoivik D.J., Tveit A., Hart S.G., Khairallah E.A., and Cohen S.D. Clofibrate pretreatment diminishes acetaminophen's selective covalent binding and hepatotoxicity. Toxicol. Appl. Pharmacol. 129 (1994) 252-263
25. Manautou J.E., Emeigh Hart S.G., Khairallah E.A., and Cohen S.D. Protection against acetaminophen hepatotoxicity by a single dose of clofibrate: effects on selective protein arylation and glutathione depletion. Fundam. Appl. Toxicol. 29 (1996) 229-237
26. Manautou J.E., Silva V.M., Hennig G.E., and Whiteley H.E. Repeated dosing with the peroxisome proliferator clofibrate decreases the toxicity of model hepatotoxic agents in male mice. Toxicology. 127 (1998) 1-10
27. Mangipudy R.S., Rao P.S., and Mehendale H.M. Effect of an antimitotic agent colchicine on thioacetamide hepatotoxicity. Environ. Health Perspect. 104 (1996) 744-749
28. Masubuchi Y., Suda C., and Horie T. Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J. Hepatol. 42 (2005) 110-116
29. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
30. Mehendale H.M. Injury and repair as opposing forces in risk assessment. Toxicol. Lett. 82-83 (1995) 891-899
31. Mehendale H.M. PPAR-alpha: a key to the mechanism of hepatoprotection by clofibrate. Toxicol. Sci. 57 (2000) 187-190
32. Mehendale H.M. Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol. Pathol. 33 (2005) 41-51
33. Mehendale H.M., and Limaye P.B. Calpain: a death protein that mediates progression of liver injury. Trends Pharmacol. Sci. 26 (2005) 232-236
34. Michalik L., Desvergne B., Tan N.S., Basu-Modak S., Escher P., Rieusset J., Peters J.M., Kaya G., Gonzalez F.J., Zakany J., Metzger D., Chambon P., Duboule D., and Wahli W. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J. Cell Biol. 154 (2001) 799-814
35. Nguyen K.A., Carbone J.M., Silva V.M., Chen C., Hennig G.E., Whiteley H.E., and Manautou J.E. The PPAR activator docosahexaenoic acid prevents acetaminophen hepatotoxicity in male CD-1 mice. J. Toxicol. Environ. Health A. 58 (1999) 171-186
36. Nicholls-Grzemski F.A., Calder I.C., and Priestly B.G. Peroxisome proliferators protect against paracetamol hepatotoxicity in mice. Biochem. Pharmacol. 43 (1992) 1395-1396
37. Nicholls-Grzemski F.A., Calder I.C., Priestly B.G., and Burcham P.C. Clofibrate-induced in vitro hepatoprotection against acetaminophen is not due to altered glutathione homeostasis. Toxicol. Sci. 56 (2000) 220-228
38. Pagano G., Pacini G., Musso G., Gambino R., Mecca F., Depetris N., Cassader M., David E., Cavallo-Perin P., and Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 35 (2002) 367-372
39. Rao V.C., and Mehendale H.M. Effect of antimitotic agent colchicine on carbon tetrachloride toxicity. Arch. Toxicol. 67 (1993) 392-400
40. Rao P.S., Mangipudy R.S., and Mehendale H.M. Tissue injury and repair as parallel and opposing responses to CCl4 hepatotoxicity: a novel dose-response. Toxicology 118 (1997) 181-193
41. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology. 121 (2001) 710-723
42. Ruepp S.U., Tonge R.P., Shaw J., Wallis N., and Pognan F. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol. Sci. 65 (2002) 135-150
43. Sahai A., Malladi P., Melin-Aldana H., Green R.M., and Whitington P.F. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 287 (2004) G264-G273
44. Sawant S.P., Dnyanmote A.V., Shankar K., Limaye P.B., Latendresse J.R., and Mehendale H.M. Potentiation of carbon tetrachloride hepatotoxicity and lethality in type 2 diabetic rats. J. Pharmacol. Exp. Ther. 308 (2004) 694-704
45. Sawant S.P., Dnyanmote A.V., Mitra M.S., Chilakapati J., Warbritton A., Latendresse J.R., and Mehendale H.M. Protective effect of type 2 diabetes on acetaminophen-induced hepatotoxicity in male Swiss-Webster mice. J. Pharmacol. Exp. Ther. 316 (2006) 507-519
46. Seidell J.C. Obesity, insulin resistance and diabetes-a worldwide epidemic. Br. J. Nutr. 83 Suppl 1 (2000) S5-S8
47. Shankar K., Vaidya V.S., Apte U.M., Manautou J.E., Ronis M.J., Bucci T.J., and Mehendale H.M. Type 1 diabetic mice are protected from acetaminophen hepatotoxicity. Toxicol. Sci. 73 (2003) 220-234
48. Shankar K., Vaidya V.S., Corton J.C., Bucci T.J., Liu J., Waalkes M.P., and Mehendale H.M. Activation of PPAR-alpha in streptozotocin-induced diabetes is essential for resistance against acetaminophen toxicity. FASEB J. 17 (2003) 1748-1750
49. Soni M.G., and Mehendale H.M. Adenosine triphosphate protection of chlordecone-amplified CCl4 hepatotoxicity and lethality. J. Hepatol. 20 (1994) 267-274
50. Soni M.G., Ramaiah S.K., Mumtaz M.M., Clewell H., and Mehendale H.M. Toxicant-inflicted injury and stimulated tissue repair are opposing toxicodynamic forces in predictive toxicology. Regul. Toxicol. Pharmacol. 29 (1999) 165-174
51. Tarantino G., Conca P., Basile V., Gentile A., Capone D., Polichetti G., and Leo E. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol. Res. 37 (2007) 410-415
52. Tharappel J.C., Nalca A., Owens A.B., Ghabrial L., Konz E.C., Glauert H.P., and Spear B.T. Cell proliferation and apoptosis are altered in mice deficient in the NF-kappaB p50 subunit after treatment with the peroxisome proliferator ciprofibrate. Toxicol. Sci. 75 (2003) 300-308
53. Vanden Heuvel J.P. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis. Toxicol. Sci. 47 (1999) 1-8
54. Weltman M.D., Farrell G.C., and Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology. 111 (1996) 1645-1653
55. Yang S., Koteish A., Lin H., Huang J., Roskams T., Dawson V., and Diehl A.M. Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. Hepatology 39 (2004) 403-411